Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Olanzapine for Preventing Nausea and Vomiting Induced by Moderately and Highly Emetogenic Chemotherapy

  • Wang, Shi-Yong (Department of Biotherapy and Laboratory of Biotherapy, the Fourth Affiliated Hospital of China Medical University) ;
  • Yang, Zhen-Jun (Department of Medical Information, Shengjing Hospital of China Medical University) ;
  • Zhang, Lu (Department of Biotherapy and Laboratory of Biotherapy, the Fourth Affiliated Hospital of China Medical University)
  • Published : 2014.12.18
Download PDF
⟨ Previous Next ⟩

Abstract

Nausea and vomiting are common adverse events in chemotherapy. In spite of the serious effects on the quality of life and further treatment, they remain overlooked by physicians, and no standard treatment has been developed. Neurokinin-1 (NK-1) receptor antagonists and palonosetron are the major agents in the standard regimen for treating moderately and highly emetogenic chemotherapy-induced nausea and vomiting (CINV). However, NK-1 receptor antagonists first became commercially available at the end of 2013 and palonosetron has not been extensively applied in China. Olanzapine was recommended as a therapy for moderate and severe CINV in antiemesis-clinical practice guidelines in oncology in 2014 for the first time. It is an atypical antipsychotic agent, which can block multiple receptors on neurotransmitters. During more than 10 years, olanzapine has demonstrated significant effects in preventing CINV and treating breakthrough and refractor CINV, which was observed in case reports, precise retrospective studies, and phase I, II and III clinical trials, with no grade 3 to 4 adverse events. In particular, it is superior to aprepitant and dexamethasone in delayed nausea and vomiting. Therefore, this compound is worthy of further investigation.

Keywords

References

  1. Brafford MV, Glode A (2014). Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting. J Adv Pract Oncol, 5, 24-9.
  2. Copier J, Bodman-Smith M, Dalgleish A (2011). Current status and future applications of cellular therapies for cancer. Immunotherapy, 3, 507-16. https://doi.org/10.2217/imt.11.18
  3. Chen W, Zheng R, Zhang S, et al (2014). Annual report on status of cancer in China, 2010. Chin J Cancer Res, 26, 48-58.
  4. Daher M (2012). Cultural beliefs and values in cancer patients. Ann Oncol, 23, 66-9. https://doi.org/10.1093/annonc/mds091
  5. Flank J, Sung L, Dvorak CC, Spettigue W, Dupuis LL (2014). The Safety of Olanzapine in Young Children: A Systematic Review and Meta-Analysis. Drug Saf . [Epub ahead of print]
  6. Hesketh PJ, Grunberg SM, Gralla RJ, et al (2003). The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol, 21, 4112-9. https://doi.org/10.1200/JCO.2003.01.095
  7. Hassan BA, Yusoff ZB (2010). Negative impact of chemotherapy on breast cancer patients QOL - utility of antiemetic treatment guidelines and the role of race. Asian Pac J Cancer Prev, 11, 1523-7.
  8. Hocking CM, Kichenadasse G. (2014). Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review. Support Care Cancer, 22, 1143-51. https://doi.org/10.1007/s00520-014-2138-y
  9. Ito F, Chang AE (2013). Cancer immunotherapy: current status and future directions. Surg Oncol Clin N Am, 22, 765-83. https://doi.org/10.1016/j.soc.2013.06.005
  10. Janelsins MC, Tejani MA, Kamen C, et al (2013). Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients. Expert Opin Pharmacother, 14, 757-66. https://doi.org/10.1517/14656566.2013.776541
  11. Keat CH, Ghani NA (2013). Cost-effectiveness analysis of granisetron-based versus standard antiemetic regimens in low-emetogenic chemotherapy: a hospital-based perspective from Malaysia. Asian Pac J Cancer Prev, 14, 7701-6. https://doi.org/10.7314/APJCP.2013.14.12.7701
  12. Li F, Zhao C, Wang L (2014). Molecular-targeted agents combination therapy for cancer: developments and potentials. Int J Cancer, 134, 1257-69. https://doi.org/10.1002/ijc.28261
  13. McIntyre RS, Cha DS, Kim RD, et al (2013). A review of FDAapproved treatment options in bipolar depression. CNS Spectr, 18, 4-20.
  14. Mizukami N, Yamauchi M, Koike K, et al (2013). Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study. J Pain Symptom Manage, [Epub ahead of print].
  15. Moore MA, Sangrajrang S, Bray F (2014). Asian cancer registry forum 2014 - regional cooperation for cancer registration: priorities and challenges. Asian Pac J Cancer Prev, 15, 1891-4. https://doi.org/10.7314/APJCP.2014.15.5.1891
  16. Navari RM, Einhorn LH, Passik SD, et al (2005). A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study. Support Care Cancer, 13, 529-34. https://doi.org/10.1007/s00520-004-0755-6
  17. Navari RM, Einhorn LH, Loehrer PJ Sr, et al (2007). A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer, 15, 1285-91. https://doi.org/10.1007/s00520-007-0248-5
  18. Navari RM, Gray SE, Kerr AC (2011). Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol, 9, 188-95. https://doi.org/10.1016/j.suponc.2011.05.002
  19. Navari RM, Nagy CK, Gray SE (2013). The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer, 21, 1655-63. https://doi.org/10.1007/s00520-012-1710-6
  20. Navari RM (2014). Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting. Eur J Pharmacol, 722, 180-6. https://doi.org/10.1016/j.ejphar.2013.08.048
  21. NCCN clinical Practice guidelines in oncology- Antiemesis Version I, 2014. http://www.nccn.org/professionals/ physician_gls/f_guidelines.asp#supportive.
  22. Pirl WF, Roth AJ (2000). Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report. Psychooncol, 9, 84-7. https://doi.org/10.1002/(SICI)1099-1611(200001/02)9:1<84::AID-PON440>3.0.CO;2-T
  23. Passik SD, Lundberg J, Kirsh KL, et al (2002). A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage, 23, 526-32. https://doi.org/10.1016/S0885-3924(02)00391-3
  24. Passik SD, Kirsh KL, Theobald DE, et al (2003). A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. J Pain Symptom Manage, 25, 485-8. https://doi.org/10.1016/S0885-3924(03)00078-2
  25. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al (2003). Cancer. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer, 97, 3090-8. https://doi.org/10.1002/cncr.11433
  26. Passik SD, Navari RM, Jung SH, et al (2004). A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. Cancer Invest, 22, 383-8. https://doi.org/10.1081/CNV-200029066
  27. Roila F, Herrstedt J, Aapro M, et al (2010). Guideline update for MASCC and ESMO in the prevention of chemotherapyand radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol, 21, 232-43. https://doi.org/10.1093/annonc/mdp300
  28. Sliwkowski MX, Mellman I (2013). Antibody therapeutics in cancer. Science, 341, 1192-8. https://doi.org/10.1126/science.1241145
  29. Siegel R, Ma J, Zou Z, et al (2014). Cancer statistics, 2014. CA Cancer J Clin, 64, 9-29. https://doi.org/10.3322/caac.21208
  30. Tan L, Liu J, Liu X, et al (2009). Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res, 28, 131. https://doi.org/10.1186/1756-9966-28-131
  31. Uchino J, Hirano R, Tashiro N, et al (2012). Efficacy of aprepitant in patients with advanced or recurrent lung cancer receiving moderately emetogenic chemotherapy. Asian Pac J Cancer Prev, 13, 4187-90. https://doi.org/10.7314/APJCP.2012.13.8.4187
  32. Vardy J, Chiew KS, Galica J, et al (2006). Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer, 94, 1011-5. https://doi.org/10.1038/sj.bjc.6603048
  33. Vig S, Seibert L, Green MR (2014). Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity. J Cancer Res Clin Oncol, 140, 77-82. https://doi.org/10.1007/s00432-013-1540-z
  34. Welti J, Loges S, Dimmeler S, et al (2013). Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer. J Clin Invest, 123, 3190-200. https://doi.org/10.1172/JCI70212
  35. Wang SY, He Y, Zhang L, et al (2014). The effects of olanzapine, tropisetron and dexamethasone to preventing the nausea and vomiting induced by multi-day highly or moderately emetogenic chemotherapy in cancer patients. Chinese clinical oncology, CSCO, 544-5.
  36. Wang XF, Feng Y, Chen Y, Gao BL, Han BH (2014). A metaanalysis of olanzapine for the prevention of chemotherapyinduced nausea and vomiting. Sci Rep, 4, 4813.
  37. Yuan Lingyan, Jiao Xiaodong, Wang Zhan, et al (2013). Olanzapine combined granisetron and dexamethasone for the prevention of chemotherapy-induced emesis and nausea in cancer patients: A phase I trial. Chinese Clin Oncol, 18, 511-4.

Cited by

  1. Prevention of Nausea and Vomiting: Methods and Utility after Surgery in Cancer Patients? vol.16, pp.7, 2015, https://doi.org/10.7314/APJCP.2015.16.7.2629
  2. Relationship between traditional Chinese medicine constitutional types with chemotherapy-induced nausea and vomiting in patients with breast cancer: an observational study vol.16, pp.1, 2016, https://doi.org/10.1186/s12906-016-1415-3
  3. Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study pp.1433-7339, 2018, https://doi.org/10.1007/s00520-018-4400-1